Table 1.
Liraglutide Effect and Diabetes (LEAD) Program, Demographic Overview
| Trial | No. of Patients | Study Duration (Weeks) | Treatment Arm | Mean Diabetes Duration (Years) | Mean Baseline HbA1c (%) | Mean FPG (mg/dL) | Mean BMI |
|---|---|---|---|---|---|---|---|
| LEAD-1 | 1,041 | 26 |
Glimepiride 2–4 mg/day plus: Liraglutide 0.6 mg daily Liraglutide 1.2 mg daily Liraglutide 1.8 mg daily Placebo Rosiglitazone 4 mg daily |
7.9 | 8.4 | 176.4 | 29.9 |
| LEAD-2 | 1,091 | 26 |
Metformin 1.5–2 g/day plus: Liraglutide 0.6mg daily Liraglutide 1.2 mg daily Liraglutide 1.8 mg daily Placebo Glimepiride 4 mg daily |
7.4 | 8.4 | 180 | 31 |
| LEAD-3 | 746 | 52 | Liraglutide 1.2 mg daily Liraglutide 1.8 mg daily Glimepiride 8 mg daily |
5.4 | 8.2 | 170.5 | 33.1 |
| LEAD-4 | 533 | 26 |
Metformin 2 g/day and rosiglitazone 8 mg/day plus: Liraglutide 1.2 mg daily Liraglutide 1.8 mg daily Placebo |
9 | 8.3 | 181.8 | 33.5 |
| LEAD-5 | 581 | 26 |
Metformin 2 g/day and glimepiride 4 mg/day plus: Liraglutide 1.8 mg daily Placebo Insulin glargine |
9.4 | 8.2 | 165.6 | 30.5 |
| LEAD-6 | 464 | 26 |
Metformin 2 g/day and/or sulfonylurea daily plus: Liraglutide 1.8 mg daily Exenatide 10 mcg twice daily |
8.2 | 8.2 | 173.7 | 32.9 |
BMI = body mass index; FPG = fasting plasma glucose; HbA1c = glycosylated hemoglobin.